NCIt definition : A humanized monoclonal antibody directed against the inhibitory receptor lymphocyte
activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities.
Upon administration, Ieramilimab binds to LAG-3 expressed on tumor-infiltrating lymphocytes
(TILs) and blocks its binding with major histocompatibility complex (MHC) class II
molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes
and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction
in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF) and expressed
on various immune cells, negatively regulates cellular proliferation and activation
of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.;
UNII : OI8P0SFD4R;
CAS number : 2137049-37-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2137049-37-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)